Penn spinout Cabaletta Bio, co-founded by Aimee Payne, MD, PhD, Adjunct Professor of Dermatology, and Michael Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis. The company also reported that the treatment was well-tolerated and successfully reduced B-cells (white blood cells that produce antibodies) within two weeks. Read more about this important drug development milestone for Cabaletta here.